Jefferies downgraded Cerevel Therapeutics (CERE) to Hold from Buy with a price target of $45, up from $40, after AbbVie (ABBV) announced plans to acquire Cerevel for $45.00 per share.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CERE: